Related Experiment Video

Updated: May 31, 2026

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)

Published on: March 14, 2019

Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel)

Dalit Modan-Moses1, Ilana Koren, Kineret Mazor-Aronovitch

  • 1Pediatric Endocrinology and Diabetes Unit, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel-Hashomer (affiliated with The Sackler School of Medicine, Tel-Aviv University), 52621 Israel. dmodan@sheba.health.gov.il

The Journal of Clinical Endocrinology and Metabolism
|June 24, 2011
PubMed

Insights

Lanreotide acetate, a long-acting somatostatin analog, offers a safe and effective alternative to continuous octreotide pump therapy for congenital hyperinsulinism (CH). This monthly injection improves patient quality of life and is well-tolerated.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Congenital hyperinsulinism (CH) is a rare genetic disorder characterized by excessive insulin secretion, leading to severe hypoglycemia.
  • Current conservative management often involves frequent feedings and medications like octreotide, administered via multiple daily injections or insulin pumps.

Observation:

  • This study reports on two pediatric patients diagnosed with CH who presented with hypoglycemia shortly after birth.
  • Both patients were initially managed with a combination of diazoxide, hydrochlorothiazide, frequent feedings, and octreotide via an insulin pump, achieving normoglycemia and good developmental outcomes.

Findings:

  • The patients were transitioned to a once-monthly deep subcutaneous injection of lanreotide acetate (30 mg), a long-acting somatostatin analog.
  • Continuous glucose monitoring confirmed normoglycemia after discontinuing octreotide pump therapy.
  • Treatment with lanreotide acetate has been well-tolerated for over 3-5 years, with patients and parents expressing satisfaction and preference for the monthly injection over pump therapy.

Implications:

  • Lanreotide acetate presents a promising, safe, and effective alternative to continuous octreotide pump therapy for managing CH.
  • The simplified dosing regimen significantly enhances the quality of life for patients and their families.
  • Further long-term studies with larger cohorts are warranted to solidify these findings.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...